Sanofi GCVRZ 深 滬
等待開盤 02-12 09:30:00 美东时间
0.8711
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 總市值 1113.52亿
- 52周最高 0.882
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 總股本 1278.30亿
- 歷史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.153
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Nektar Therapeutics Stock Gaining Wednesday?
Nektar Therapeutics stock surged after positive data showed sustained and deepening disease control with its eczema therapy.
02-11 20:35
FDA Refuses To Review Moderna's Influenza Shot Application
Moderna stock fell as FDA refused to review its influenza vaccine due to choice of comparator; CEO requests meeting for clarification.
02-11 18:21
Oakmark International Strategy adds Unilever, Sanofi in Q4, exits Novartis
Oakmark International Strategy returned 4.93% in Q4, underperforming its benchmark MSCI World ex USA Index's 5.20% gain. During the quarter, the strategy fund initiated a position in AstraZeneca (AZN)...
02-10 22:33
Sanofi’s rilzabrutinib gains breakthrough therapy status in US, orphan drug designation in Japan
Sanofi’s (SNY) rilzabrutinib has been granted breakthrough therapy designation in the United States and orphan drug status in Japan for treating warm autoimmune hemolytic anemia, the drugmaker said o...
02-09 14:33
BRIEF-Sanofi Says Rilzabrutinib Designated Breakthrough Therapy In US
BRIEF-Sanofi Says Rilzabrutinib Designated Breakthrough Therapy In US Feb 9 (Reuters) - Sanofi SA SASY.PA : RILZABRUTINIB DESIGNATED BREAKTHROUGH THERAPY IN US JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE HAS ALSO PROVIDED RILZABRUTINIB AN ORPHAN DESIGNATION FOR SAME CONDITION BOTH DESIGNATIONS A
02-09 14:04
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Entera Bio Ltd. has appointed Geno J. Germano as its new Chairman, succeeding Gerald Lieberman. Germano, with over three decades of leadership experience in the biopharmaceutical industry, including senior roles at Pfizer and Wyeth, will guide Entera during a pivotal phase as the company advances two oral peptide programs into clinical trials in 2026: a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in...
02-09 13:50
UPDATE 4-Trump unveils TrumpRx discounted drugs website
UPDATE 4-Trump unveils TrumpRx discounted drugs website TrumpRx.gov to offer discounted drugs via GoodRx, not direct sales Deals with major drugmakers include Eli Lilly, Novo Nordisk, Merck TrumpRx targets cash-paying consumers without insurance Updates with WH event, website online in paragraph 2,
02-06 00:24
BUZZ-Perspective Therapeutics jumps after $175 mln equity offering
BUZZ-Perspective Therapeutics jumps after $175 mln equity offering ** Radiation oncology firm Perspective Therapeutics CATX.A shares up 17.3% at $4.44 on Mon after $175 mln follow-on offering ** CATX early Mon announced pricing 46.2 mln shares, including ~6.6 mln pre-funded warrants, at $3.79, in li
02-02 23:34
Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation
The European Medicine Association's Committee for Medicinal Products for Human Use has given a positive recommendation for conditional approval to Sanofi's (SNY) chronic graft-versus-host disease trea...
01-30 21:51
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms Changes dateline, adds Eli Lilly details in paragraph 11 Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded
01-30 20:07
